Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

INTRODUCTION: Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, April, Paul, Carle, Puig, Luis, Boehncke, Wolf Henning, Freeman, Michael, Torii, Hideshi, Papp, Kim, Griffiths, Christopher E. M., Blauvelt, Andrew, Reich, Kristian, Gooderham, Melinda, Terui, Tadashi, Renda, Lisa, Agada, Noah, Xu, Wen, Gallo, Gaia, Lebwohl, Mark G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994584/
https://www.ncbi.nlm.nih.gov/pubmed/31749092
http://dx.doi.org/10.1007/s13555-019-00340-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994584/
https://www.ncbi.nlm.nih.gov/pubmed/31749092
http://dx.doi.org/10.1007/s13555-019-00340-3

Ejemplares similares